Journey Medical Q1 EPS $(0.30) Beats $(0.45) Estimate, Sales $12.21M Miss $16.18M Estimate
Portfolio Pulse from Benzinga Newsdesk
Journey Medical (NASDAQ:DERM) reported Q1 losses of $(0.30) per share, beating the $(0.45) estimate by 33.33%. However, sales of $12.21M missed the $16.18M estimate by 24.52%, a 47.57% decrease YoY.
May 22, 2023 | 8:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Journey Medical's Q1 EPS of $(0.30) beat estimates, but sales of $12.21M missed the $16.18M estimate, down 47.57% YoY.
Journey Medical's Q1 earnings beat estimates, which could have a positive impact on the stock. However, the significant decrease in sales YoY and missing the sales estimate could offset any potential gains, resulting in a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100